COVID-19
– Findings show viral proteins outside of Spike across Alpha, Beta, Gamma, Delta and Omicron SARS-CoV-2 variants are responsible for innate immune suppression and escape from human immune system barriers – Elucidation of common evolutionary thread provides key biologic target against future COVID-19 variants and other pandemics Excerpt from the Press Release: SAN FRANCISCO and…
Read More
Excerpt from the Press Release: BOSTON, MASSACHUSETTS, Aug. 24, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA), to…
Read More
Excerpt from the Press Release: WALTHAM, Mass., June 22, 2023 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced positive initial data from its ongoing Phase 1 healthy volunteer clinical trial of its lead investigational monoclonal antibody (mAb) candidate,…
Read More
— Potent and durable immunogenicity achieved with low dose self-amplifying mRNA vaccine (samRNA) candidate — — Immunity boosted for at least 6 months in previously vaccinated-older adults (administration post-primary series of Vaxzevria®, Comirnaty® or Spikevax®) — — Data underscore the potential of Gritstone’s samRNA candidates to serve as next-generation vaccines against COVID-19 and other infectious…
Read More
Excerpt from the Press Release: LA JOLLA, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Health Canada has completed its review of the clinical trial application and has granted…
Read More
Excerpt from the Press Release: Clinical study on nasopharyngeal cancer with an unexpected result. Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Scientists feared that vaccination against COVID-19 could reduce the success of cancer treatment or cause severe side effects—until now. A recent study now gives…
Read More
–Study also suggests vaccine timing is important in maximizing concentration of antibodies transferred to the baby– Excerpt from the Press Release: PHILADELPHIA, Nov. 9, 2022 /PRNewswire/ –Pregnant people who received one of the mRNA COVID-19 vaccines had 10-fold higher antibody concentrations than those who were naturally infected with SARS-CoV-2, a finding that was also…
Read More
A reduction in the risk of early death or respiratory failure at day 28 of 45% in the Intent-To-Treat (ITT) population and 53% in the Per Protocol (PP) population A reduction in the risk of death at day 90 of 43% in the ITT population and 70% in the PP population The start of regulatory…
Read More
Excerpt from the Press Release: PLYMOUTH MEETING, Pa., Oct. 27, 2022 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced that it has discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster…
Read More
Initiation of first clinical study of multivalent VBI-2901, designed to increase breadth of protection against COVID-19 and related coronaviruses Preclinical data support broadly reactive immunity of VBI-2901 against a panel of coronavirus variants in mice, which now also includes circulating BA.4 and BA.5 The study is expected to enroll approximately 100 adults in Canada and…
Read More